Ovarian Cancer News From Yahoo News
BiPar Sciences Expands Phase 2 Clinical Trials Of BSI-201, A Novel DNA Repair Inhibitor, In Ovarian Cancer (Medical News Today)
BiPar Sciences, Inc. announced the expansion of Phase 2 clinical trial programs for its lead product, BSI-201, in ovarian cancer. This is the third major clinical trial of BSI-201 that BiPar has launched in the past 6 months, expanding on on going trials in breast and brain cancer. Fri, 09 May 2008 08:12:59 GMT
Experts raising awareness of ovarian cancer (ABC via Yahoo!7 News)
The importance of early detection of ovarian cancer is being discussed at a national gynaecological onocologists conference on in Tasmania. Thu, 08 May 2008 06:00:00 GMT
BiPar Sciences Expands Phase 2 Clinical Trials of BSI-201, a Novel DNA Repair Inhibitor, in Ovarian Cancer (PR Newswire via Yahoo! Finance)
BiPar Sciences, Inc. today announced the expansion of Phase 2 clinical trial programs for its lead product, BSI-201, in ovarian cancer. This is the third major clinical trial of BSI-201 that BiPar has launched in the past 6 months, expanding on on-going trials in breast and brain cancer. Thu, 08 May 2008 12:00:00 GMT
|